Madison Asset Management LLC Acquires 15,459 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Madison Asset Management LLC boosted its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 33.0% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,363 shares of the company's stock after acquiring an additional 15,459 shares during the period. Madison Asset Management LLC's holdings in Genmab A/S were worth $1,221,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Genmab A/S during the fourth quarter valued at approximately $2,463,000. GAMMA Investing LLC boosted its stake in Genmab A/S by 1,465.3% during the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after purchasing an additional 31,343 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Genmab A/S by 18.8% in the fourth quarter. Northern Trust Corp now owns 599,381 shares of the company's stock valued at $12,509,000 after buying an additional 94,858 shares during the period. LPL Financial LLC grew its holdings in Genmab A/S by 3.3% during the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after acquiring an additional 6,288 shares during the period. Finally, Sei Investments Co. lifted its holdings in Genmab A/S by 55.2% in the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after acquiring an additional 20,525 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on GMAB shares. HC Wainwright restated a "buy" rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Wall Street Zen cut shares of Genmab A/S from a "buy" rating to a "hold" rating in a report on Sunday, July 20th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.80.

Genmab A/S Price Performance

Genmab A/S stock traded down $0.23 during trading hours on Friday, hitting $23.40. The company had a trading volume of 713,820 shares, compared to its average volume of 1,079,586. The firm has a market cap of $15.01 billion, a PE ratio of 13.30, a PEG ratio of 7.18 and a beta of 0.94. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $28.56. The firm has a 50-day moving average of $21.49 and a 200 day moving average of $20.82.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The business had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. As a group, research analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.